PharmaRadar360

PharmaRadar360

Pharmaceutical research team working in a modern facility

FDA novel drug approvals 2025

New molecular entities and new therapeutic biologics approved by FDA's CDER in 2025, from Drugs@FDA records (original applications of submission class Type 1, counted once per active ingredient). Each entry links to its Drugs@FDA record. New approvals can take several days to appear in Drugs@FDA; FDA's own list is Novel Drug Approvals for 2025.

46 novel approvals · Drugs@FDA data as of Oct 13, 2026.

NDAApproved Dec 30, 2025VANDA PHARMS INCNDA220152

Nereus

tradipitant

BLAApproved Dec 23, 2025Priority reviewOMEROS CORPBLA761152

Yartemlea

narsoplimab-wuug

NDAApproved Dec 19, 2025CYTOKINETICSNDA219083

Myqorzo

aficamten

BLAApproved Dec 16, 2025GLAXOSMITHKLINE LLCBLA761458

Exdensur

depemokimab-ulaa

NDAApproved Dec 12, 2025MILESTONE PHARMS USANDA218571

Cardamyst

etripamil

BLAApproved Dec 12, 2025LIB THERAPEUTICS, INC.BLA761427

Lerochol

lerodalcibep-liga

NDAApproved Dec 12, 2025Priority reviewENTASIS THERAPNDA219491

Nuzolvence

zoliflodacin

BLAApproved Nov 25, 2025Priority reviewOTSUKA PHARM CO LTDBLA761434

Voyxact

sibeprenlimab-szsi

NDAApproved Nov 19, 2025Priority reviewBAYER HEALTHCARENDA219972

Hyrnuo

sevabertinib

NDAApproved Nov 18, 2025ARROWHEADNDA219947

Redemplo

plozasiran sodium

NDAApproved Nov 13, 2025Priority reviewKURANDA220305

Komzifti

ziftomenib

NDAApproved Nov 3, 2025Priority reviewUCB INCNDA219792

Kygevvi

doxecitine and doxribtimine

NDAApproved Oct 24, 2025BAYER HLTHCARENDA219469

Lynkuet

elinzanetant

NDAApproved Oct 7, 2025Priority reviewBOEHRINGER INGELHEIMNDA218764

Jascayd

nerandomilast

NDAApproved Sep 30, 2025Priority reviewNOVARTISNDA218436

Rhapsido

remibrutinib

NDAApproved Sep 25, 2025ELI LILLY AND CONDA218881

Inluriyo

imlunestrant tosylate

NDAApproved Sep 25, 2025CRINETICSNDA219070

Palsonify

paltusotine hydrochloride

NDAApproved Sep 19, 2025Priority reviewSTEALTH BIOTHERAPSNDA215244

Forzinity

elamipretide hydrochloride

BLAApproved Sep 19, 2025Priority reviewMERCK SHARP DOHMEBLA761467

Keytruda Qlex

pembrolizumab and berahyaluronidase alfa-pmph

NDAApproved Aug 29, 2025GENZYME CORPNDA219685

Wayrilz

rilzabrutinib

NDAApproved Aug 21, 2025IONIS PHARMS INCNDA219407

Dawnzera (autoinjector)

donidalorsen sodium

NDAApproved Aug 12, 2025Priority reviewINSMED INCNDA217673

Brinsupri

brensocatib

NDAApproved Aug 8, 2025Priority reviewBOEHRINGER INGELHEIMNDA219042

Hernexeos

zongertinib

NDAApproved Aug 6, 2025Priority reviewCHIMERIXNDA219876

Modeyso

dordaviprone hydrochloride

NDAApproved Jul 31, 2025LENZ THERAPNDA218585

Vizz

aceclidine hydrochloride

NDAApproved Jul 28, 2025PTC THERAPNDA219666

Sephience

sepiapterin

NDAApproved Jul 23, 2025LEO PHARMA ASNDA219155

Anzupgo

delgocitinib

NDAApproved Jul 3, 2025KALVISTANDA219301

Ekterly

sebetralstat

BLAApproved Jul 2, 2025Priority reviewRENGENERON PHARMACEUTICALS, INC.BLA761400

Lynozyfic

linvoseltamab-gcpt

NDAApproved Jul 2, 2025Priority reviewDIZALNDA219839

Zegfrovy

sunvozertinib

BLAApproved Jun 16, 2025CSL BEHRING LLCBLA761367

Andembry

garadacimab-gxii

NDAApproved Jun 11, 2025Priority reviewNUVATIONNDA219713

Ibtrozi

taletrectinib adipate

BLAApproved Jun 9, 2025Priority reviewMERCK SHARP DOHMEBLA761432

Enflonsia

clesrovimab-cfor

NDAApproved May 28, 2025ALCON LABS INCNDA217370

Tryptyr

acoltremon

BLAApproved May 14, 2025Priority reviewABBVIE INCBLA761384

Emrelis

telisotuzumab vedotin-tllv

NDAApproved May 8, 2025Priority reviewVERASTEM INCNDA219616

Avmapki Fakzynja Co-Pack (copackaged)

avutometinib potassium and defactinib hydrochloride

BLAApproved Apr 29, 2025Priority reviewJANSSEN BIOTECHBLA761430

Imaavy

nipocalimab-aahu

BLAApproved Apr 23, 2025AKESO BIOPHARMABLA761258

Penpulimab-Kcqx

penpulimab-kcqx

NDAApproved Apr 2, 2025NOVARTISNDA219208

Vanrafia

atrasentan hydrochloride

NDAApproved Mar 28, 2025GENZYME CORPNDA219019

Qfitlia

fitusiran sodium

NDAApproved Mar 25, 2025Priority reviewGLAXOSMITHKLINENDA218230

Blujepa

gepotidacin mesylate

NDAApproved Feb 14, 2025Priority reviewDECIPHERA PHARMSNDA219304

Romvimza

vimseltinib

NDAApproved Feb 11, 2025Priority reviewSPRINGWORKSNDA219379

Gomekli

mirdametinib

NDAApproved Jan 30, 2025Priority reviewVERTEX PHARMS INCNDA219209

Journavx

suzetrigine

NDAApproved Jan 21, 2025MEDEXUSNDA214759

Grafapex

treosulfan

BLAApproved Jan 17, 2025DAIICHI SANKYO INCBLA761394

Datroway

datopotamab deruxtecan-dlnk